This site is intended for health professionals only
Saturday 23 June 2018
Share |

Tivozanib now licensed in the European Union for first-line treatment

Related articles

A report from the charity Cancer Research UK has called on the health service to prepare for a large increase in the number of over 75s with cancer
Manufacturer Amgen has received approval from the European Commission (EC) to include overall survival (OS) data on the labels of the drug BLINCYTO (blinatumomab), it has announced.
International team of researchers have developed new DNA test to identify men at greatest risk of prostate cancer
Cancer fighting effects of aspirin revealed in bowel tumour study

EUSA Pharma has announced that the European Commission (EC) has licensed Fotivda® for the management of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland.

Ads by Google